The PBAC rejected a request from MSD to restrict ‘a-flagging’ of its etanercept biosimilar Brenzys to patients who are naïve to the molecule, minutes from its July meeting reveal. According to the PBAC it turned down the request out of a belief the concept would not work in practice. “It relies on the dispenser knowing whether ...
Treatment naive ‘a-flagging’ would not work: PBAC
10 Nov 2016